Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
The firm made the announcements as part of its Q1 financial report, in which it posted $2.99 billion in revenue, up 8 percent ...
Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 ...
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...
In cystic fibrosis, ETI significantly reduced daily cough frequency and increased physical activity levels in patients aged 12 and older.
Pharmacology has a cation bias. For too long, research has focused heavily on sodium and potassium channels, often treating anion transport as a secondary ...
CFTR modulators, especially triple therapy, significantly improve sinonasal inflammation and nasal polyp size in patients with cystic fibrosis.
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Topline data is on track for anticipated readout in the summer of 2026WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- ...
Scientists have used prime editing to permanently correct nonsense mutations in the CFTR gene, which cause cystic fibrosis in about 10% of patients who do not benefit from existing drugs. The method ...
Morning Overview on MSN
Gene therapy targets rare cystic fibrosis mutation affecting ~10%
For roughly one in ten people living with cystic fibrosis, the drugs that have transformed survival for most CF patients are ...
Moats come in many forms, from brand strength to a solid patent portfolio. A company may be a leader in its field today, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results